Prognostic value of the preoperative systemic immune-inflammation nutritional index in patients with gastric cancer.

IF 2.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-04-24 DOI:10.5306/wjco.v16.i4.102294

Li-Jing Wang, Cai-Lu Lei, Ting-An Wang, Zhi-Feng Lin, Shi-Jie Feng, Tao Wei, Yan-Qin Li, Meng-Ru Shen, Yan Li, Liu-Feng Liao

{"title":"Prognostic value of the preoperative systemic immune-inflammation nutritional index in patients with gastric cancer.","authors":"Li-Jing Wang, Cai-Lu Lei, Ting-An Wang, Zhi-Feng Lin, Shi-Jie Feng, Tao Wei, Yan-Qin Li, Meng-Ru Shen, Yan Li, Liu-Feng Liao","doi":"10.5306/wjco.v16.i4.102294","DOIUrl":null,"url":null,"abstract":"Background: Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related deaths in China. Many patients with GC frequently experience symptoms related to the disease, including anorexia, nausea, vomiting, and other discomforts, and often suffer from malnutrition, which in turn negatively affects perioperative safety, prognosis, and the effectiveness of adjuvant therapeutic measures. Consequently, some nutritional indicators such as nutritional risk index (NRI), prognostic nutritional index (PNI), and systemic immune-inflammatory-nutritional index (SIINI) can be used as predictors of the prognosis of GC patients.Aim: To examine the prognostic significance of PNI, NRI, and SIINI in postoperative patients with GC.Methods: A retrospective analysis was conducted on the clinical data of patients with GC who underwent surgical treatment at the Guangxi Medical University Cancer Hospital between January 2010 and December 2018. The area under the receiver operating characteristic (ROC) curve was assessed using ROC curve analysis, and the optimal cutoff values for NRI, PNI, and SIINI were identified using the You-Review-HTMLden index. Survival analysis was performed using the Kaplan-Meier method. In addition, univariate and multivariate analyses were conducted using the Cox proportional hazards regression model.Results: This study included a total of 803 patients. ROC curves were used to evaluate the prognostic ability of NRI, PNI, and SIINI. The results revealed that SIINI had superior predictive accuracy. Survival analysis indicated that patients with GC in the low SIINI group had a significantly better survival rate than those in the high SIINI group (P < 0.05). Univariate analysis identified NRI [hazard ratio (HR) = 0.68, 95% confidence interval (CI): 0.52-0.89, P = 0.05], PNI (HR = 0.60, 95%CI: 0.46-0.79, P < 0.001), and SIINI (HR = 2.10, 95%CI: 1.64-2.69, P < 0.001) as prognostic risk factors for patients with GC. However, multifactorial analysis indicated that SIINI was an independent risk factor for the prognosis of patients with GC (HR = 1.65, 95%CI: 1.26-2.16, P < 0.001).Conclusion: Analysis of clinical retrospective data revealed that SIINI is a valuable indicator for predicting the prognosis of patients with GC. Compared with NRI and PNI, SIINI may offer greater application for prognostic assessment.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102294"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019271/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i4.102294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related deaths in China. Many patients with GC frequently experience symptoms related to the disease, including anorexia, nausea, vomiting, and other discomforts, and often suffer from malnutrition, which in turn negatively affects perioperative safety, prognosis, and the effectiveness of adjuvant therapeutic measures. Consequently, some nutritional indicators such as nutritional risk index (NRI), prognostic nutritional index (PNI), and systemic immune-inflammatory-nutritional index (SIINI) can be used as predictors of the prognosis of GC patients.

Aim: To examine the prognostic significance of PNI, NRI, and SIINI in postoperative patients with GC.

Methods: A retrospective analysis was conducted on the clinical data of patients with GC who underwent surgical treatment at the Guangxi Medical University Cancer Hospital between January 2010 and December 2018. The area under the receiver operating characteristic (ROC) curve was assessed using ROC curve analysis, and the optimal cutoff values for NRI, PNI, and SIINI were identified using the You-Review-HTMLden index. Survival analysis was performed using the Kaplan-Meier method. In addition, univariate and multivariate analyses were conducted using the Cox proportional hazards regression model.

Results: This study included a total of 803 patients. ROC curves were used to evaluate the prognostic ability of NRI, PNI, and SIINI. The results revealed that SIINI had superior predictive accuracy. Survival analysis indicated that patients with GC in the low SIINI group had a significantly better survival rate than those in the high SIINI group (P < 0.05). Univariate analysis identified NRI [hazard ratio (HR) = 0.68, 95% confidence interval (CI): 0.52-0.89, P = 0.05], PNI (HR = 0.60, 95%CI: 0.46-0.79, P < 0.001), and SIINI (HR = 2.10, 95%CI: 1.64-2.69, P < 0.001) as prognostic risk factors for patients with GC. However, multifactorial analysis indicated that SIINI was an independent risk factor for the prognosis of patients with GC (HR = 1.65, 95%CI: 1.26-2.16, P < 0.001).

Conclusion: Analysis of clinical retrospective data revealed that SIINI is a valuable indicator for predicting the prognosis of patients with GC. Compared with NRI and PNI, SIINI may offer greater application for prognostic assessment.

查看原文本刊更多论文

术前全身免疫-炎症营养指数对胃癌患者预后的价值。

背景：胃癌（GC）是中国第五大常见癌症和第三大癌症相关死亡原因。许多胃癌患者经常出现厌食、恶心、呕吐等疾病相关症状，并经常出现营养不良，这反过来又对围手术期的安全性、预后和辅助治疗措施的有效性产生负面影响。因此，一些营养指标如营养风险指数（NRI）、预后营养指数（PNI）和全身免疫-炎症-营养指数（SIINI）可作为胃癌患者预后的预测指标。目的：探讨PNI、NRI和SIINI在胃癌术后患者预后中的意义。方法：回顾性分析2010年1月至2018年12月广西医科大学肿瘤医院手术治疗的胃癌患者的临床资料。采用ROC曲线分析评估受试者工作特征（ROC）曲线下面积，采用You-Review-HTMLden指数确定NRI、PNI和SIINI的最佳截止值。采用Kaplan-Meier法进行生存分析。此外，采用Cox比例风险回归模型进行单因素和多因素分析。结果：本研究共纳入803例患者。采用ROC曲线评价NRI、PNI和SIINI的预后能力。结果显示，SIINI具有优越的预测准确性。生存分析显示，低SIINI组胃癌患者的生存率明显高于高SIINI组（P < 0.05）。单因素分析确定NRI[危险比(HR) = 0.68, 95%可信区间（CI）： 0.52-0.89, P = 0.05]、PNI （HR = 0.60, 95%CI: 0.46-0.79, P < 0.001）和SIINI （HR = 2.10, 95%CI: 1.64-2.69, P < 0.001）为GC患者的预后危险因素。然而，多因素分析显示SIINI是影响胃癌患者预后的独立危险因素（HR = 1.65, 95%CI: 1.26 ~ 2.16, P < 0.001）。结论：临床回顾性资料分析显示，SIINI是预测胃癌患者预后的重要指标。与NRI和PNI相比，SIINI在预后评估方面可能有更大的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.